Chardan Capital Reiterates “Buy” Rating for Gain Therapeutics (NASDAQ:GANX)

Gain Therapeutics (NASDAQ:GANX)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a note issued to investors on Friday,Benzinga reports. They presently have a $6.00 target price on the stock. Chardan Capital’s price objective points to a potential upside of 217.46% from the stock’s current price.

A number of other research analysts have also recently issued reports on the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research note on Monday, March 17th. Roth Mkm restated a “buy” rating and set a $7.00 price target on shares of Gain Therapeutics in a research report on Tuesday, December 24th. Scotiabank initiated coverage on Gain Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price target on the stock. Finally, Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Gain Therapeutics currently has a consensus rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Stock Down 8.7 %

Shares of GANX opened at $1.89 on Friday. Gain Therapeutics has a 1 year low of $0.89 and a 1 year high of $4.04. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. The stock has a 50 day simple moving average of $2.22 and a two-hundred day simple moving average of $2.06. The firm has a market cap of $50.13 million, a P/E ratio of -1.72 and a beta of 0.14.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.07. On average, analysts forecast that Gain Therapeutics will post -1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of GANX. Marshall Wace LLP purchased a new position in shares of Gain Therapeutics during the fourth quarter valued at approximately $198,000. Geode Capital Management LLC boosted its holdings in Gain Therapeutics by 48.0% in the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after acquiring an additional 88,236 shares in the last quarter. Jones Financial Companies Lllp increased its position in Gain Therapeutics by 83.6% during the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock valued at $212,000 after purchasing an additional 44,750 shares during the period. Northern Trust Corp raised its holdings in Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock worth $183,000 after purchasing an additional 39,642 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new stake in shares of Gain Therapeutics in the 4th quarter worth about $65,000. Institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.